Excited for all the big changes for Polpharma and Rezon, and not all of them are about the new brand. This business has hired some of the best talent to drive growth, and will be led by the new CEO, Dr. Adriana Kiędzierska-Mencfeld
Excited for all the big changes for Polpharma and Rezon, and not all of them are about the new brand. This business has hired some of the best talent to drive growth, and will be led by the new CEO, Dr. Adriana Kiędzierska-Mencfeld
That’s Nice is pleased to be able to support the launch of a new biologics CDMO based in Poland. This business split from Polpharma Biologics, which will now focus exclusively on biosimilars.
Throwback to Nigel and Russell at the booth we developed for GSK at CPHI 2016 in Frankfurt.
We are excited to support PPD’s Trialmed division in its mission to revolutionize clinical trials for sponsors and patients alike.
A bittersweet moment as the industry congratulates our longtime colleague and collaborator, Nick Green, on a well-deserved retirement.
It was a pleasure to visit such a well-run GLP lab at FairJourney Biologics’ headquarters in Porto, Portugal.
A fascinating presentation from Dr. Hollanbaugh, highlighting the discussion around Interleukin-2 (IL-2) inhibitors, which have emerged as a pivotal class of therapeutic agents, particularly in the realm of immunology and oncology.
Day Two of TAS25 kicks off with a presentation by Professor Madelon Maurice from the Madelon Maurice Lab in Holland.
Peter Senter, Ph.D., Janine Schuurman, Ph.D., and Greg Thurber, Ph.D. — now that’s a lineup.
Peter Senter, Ph.D., is the keynote for TAS25. Peter joined Seattle Genetics in 1998 and was part of the research team focused on anticancer therapies before the company’s $43 billion sale to Pfizer in 2023.